Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 August 2022 | Story Edzani Nephalela and Coreen Steenkamp | Photo Francois van Vuuren
Academic Leadership Programme
The new cohort of the Academic Leadership Programme.

Educational leaders serve a significant administrative, management, and leadership function in higher education. A departmental chair’s role differs fundamentally from other leadership contexts, based on the momentous transition from being an academic by profession to providing leadership at departmental level.
The Academic Leadership Programme (APL) was launched by the University of the Free State (UFS) Centre for Teaching and Learning (CTL) to equip academics for various managerial positions. Faculty deans propose candidates for this programme; the second cohort has been chosen as the first is nearing completion. 
The first workshop commenced with an engagement with the Rector and Vice-Chancellor of the UFS, Prof Francis Petersen, and the Vice-Rector: Academic, Dr Engela van Staden, who both shared strategic academic leadership perspectives during the orientation and welcoming of the APL. 
Such reflections highlighted the expectations of being an educator, the complexity, and the critical role of departmental chairs within higher education institutions. Academic leaders are thus expected to establish firm leadership within their departments, facilitate intellectual development, manage administrative duties, and strive toward resilient learning and teaching environments. 
“The position of departmental chairs remains critical for any higher education institution, as they provide leadership in advancing the discipline, teaching students, producing quality graduates, and serving the professional community,” said Prof Francois Strydom, Senior Director: Centre for Teaching and Learning.
Research confirms that most academics succeed in these roles without formal leadership training, yet the expectation of developing or having certain leadership qualities or management competencies must fulfil the various functions of such a position. 


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept